1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and gene therapy quality control and analytics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and gene therapy quality control and analytics Market, by Testing Type
8.1.1. Sterility Testing
8.1.1.1. Market Revenue and Forecast
8.1.2. Identity Testing
8.1.2.1. Market Revenue and Forecast
8.1.3. Potency Testing
8.1.3.1. Market Revenue and Forecast
8.1.4. Mycoplasma Testing
8.1.4.1. Market Revenue and Forecast
8.1.5. Endotoxin Testing
8.1.5.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Cell and gene therapy quality control and analytics Market, by Analytical Method
9.1.1. Flow Cytometry
9.1.1.1. Market Revenue and Forecast
9.1.2. Polymerase Chain Reaction (PCR)
9.1.2.1. Market Revenue and Forecast
9.1.3. High-Performance Liquid Chromatography (HPLC)
9.1.3.1. Market Revenue and Forecast
9.1.4. Mass Spectrometry
9.1.4.1. Market Revenue and Forecast
9.1.5. Enzyme-Linked Immunosorbent Assay (ELISA)
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Cell and gene therapy quality control and analytics Market, by Application Area
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Genetic Disorders
10.1.2.1. Market Revenue and Forecast
10.1.3. Cardiovascular Diseases
10.1.3.1. Market Revenue and Forecast
10.1.4. Infectious Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Cell and gene therapy quality control and analytics Market, by End-User
11.1.1. Pharmaceutical & Biotechnology Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Development and Manufacturing Organizations (CDMOs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Testing Type
12.1.2. Market Revenue and Forecast, by Analytical Method
12.1.3. Market Revenue and Forecast, by Application Area
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Testing Type
12.1.5.2. Market Revenue and Forecast, by Analytical Method
12.1.5.3. Market Revenue and Forecast, by Application Area
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Testing Type
12.1.6.2. Market Revenue and Forecast, by Analytical Method
12.1.6.3. Market Revenue and Forecast, by Application Area
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Testing Type
12.2.2. Market Revenue and Forecast, by Analytical Method
12.2.3. Market Revenue and Forecast, by Application Area
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Testing Type
12.2.5.2. Market Revenue and Forecast, by Analytical Method
12.2.5.3. Market Revenue and Forecast, by Application Area
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Testing Type
12.2.6.2. Market Revenue and Forecast, by Analytical Method
12.2.6.3. Market Revenue and Forecast, by Application Area
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Testing Type
12.2.7.2. Market Revenue and Forecast, by Analytical Method
12.2.7.3. Market Revenue and Forecast, by Application Area
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Testing Type
12.2.8.2. Market Revenue and Forecast, by Analytical Method
12.2.8.3. Market Revenue and Forecast, by Application Area
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Testing Type
12.3.2. Market Revenue and Forecast, by Analytical Method
12.3.3. Market Revenue and Forecast, by Application Area
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Testing Type
12.3.5.2. Market Revenue and Forecast, by Analytical Method
12.3.5.3. Market Revenue and Forecast, by Application Area
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Testing Type
12.3.6.2. Market Revenue and Forecast, by Analytical Method
12.3.6.3. Market Revenue and Forecast, by Application Area
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Testing Type
12.3.7.2. Market Revenue and Forecast, by Analytical Method
12.3.7.3. Market Revenue and Forecast, by Application Area
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Testing Type
12.3.8.2. Market Revenue and Forecast, by Analytical Method
12.3.8.3. Market Revenue and Forecast, by Application Area
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Testing Type
12.4.2. Market Revenue and Forecast, by Analytical Method
12.4.3. Market Revenue and Forecast, by Application Area
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Testing Type
12.4.5.2. Market Revenue and Forecast, by Analytical Method
12.4.5.3. Market Revenue and Forecast, by Application Area
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Testing Type
12.4.6.2. Market Revenue and Forecast, by Analytical Method
12.4.6.3. Market Revenue and Forecast, by Application Area
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Testing Type
12.4.7.2. Market Revenue and Forecast, by Analytical Method
12.4.7.3. Market Revenue and Forecast, by Application Area
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Testing Type
12.4.8.2. Market Revenue and Forecast, by Analytical Method
12.4.8.3. Market Revenue and Forecast, by Application Area
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Testing Type
12.5.2. Market Revenue and Forecast, by Analytical Method
12.5.3. Market Revenue and Forecast, by Application Area
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Testing Type
12.5.5.2. Market Revenue and Forecast, by Analytical Method
12.5.5.3. Market Revenue and Forecast, by Application Area
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Testing Type
12.5.6.2. Market Revenue and Forecast, by Analytical Method
12.5.6.3. Market Revenue and Forecast, by Application Area
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. WuXi AppTec
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bio-Techne Corporation
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Lonza Group
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Merck KGaA
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bio-Rad Laboratories
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. QIAGEN
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. F. Hoffmann-La Roche Ltd.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Samsung Biologics
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Sangamo Therapeutics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
